SCHEMBL4248559

SCHEMBL4248559

O=C1C2CNCC1CNC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 6/20 0.38
CHRNA3 P32297 6/20 0.38
CCR5 P51681 1/20 0.35
CHRNB2 P17787 9/20 0.35
CHRNA4 P43681 9/20 0.35
MAN1B1 Q9UKM7 1/20 0.32
KDM4E B2RXH2 2/20 0.31
CYP3A4 P08684 2/20 0.31
CHRNA1 P02708 2/20 0.31
CHRNG P07510 2/20 0.31
CHRNB1 P11230 2/20 0.31
CHRNA7 P36544 2/20 0.31
CHRND Q07001 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
ESR1 P03372 1/20 0.31
CHRNA5 P30532 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26976760 0.97 CHRNB4 (0.36) CHRNB4CHRNA3CCR5CHRNB2CHRNA4
SCHEMBL7527940 0.87
SCHEMBL30741886 0.87
SCHEMBL27115171 0.87
Hydrochloric Acid SCHEMBL25259741 0.84 CHRNB4 (0.33) CHRNB4CHRNA3CCR5CHRNB2CHRNA4
SCHEMBL9636603 0.82 SMN1; SMN2 (0.33) CHRNB4CHRNA3CHRNB2CHRNA4HTR3A
SCHEMBL14529644 0.82 DAO (0.37) CHRNB4CHRNA3CHRNB2CHRNA4HTR3A
SCHEMBL22965580 0.82 SMN1; SMN2 (0.33) CHRNB4CHRNA3CHRNB2CHRNA4HTR3A
Hydrochloric Acid SCHEMBL14335830 0.80 CHRNB2 (0.33) CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL9585542 0.80 CHRNB4 (0.31) CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570851-B2 Liquids MILLIKEN INDUSTRIALS LIMITED (GB) 2026-03-10 US disclosed
EP-4596564-A1 METHOD FOR PREPARING A HOMOGENEOUS SOLUTION OF A METAL BISPIDONE CHELATE COMPLEX FOR OXIDATIVELY DRYING SYSTEMS hubergroup Deutschland GmbH (DE) 2025-08-06 EP disclosed
US-12077652-B2 Oxidatively curable coating composition MILLIKEN INDUSTRIALS LIMITED (GB) 2024-09-03 US disclosed
EP-4172283-A1 PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING ANIONS OF SULFONIC ACIDS AS COUNTER IONS Borchers GmbH (DE) 2023-05-03 EP disclosed
US-20220073735-A1 LIQUIDS Borchers Catalyst (UK) Limited (GB) 2022-03-10 US disclosed
US-20220073701-A1 OXIDATIVELY CURABLE COATING COMPOSITION CATEXEL TECHNOLOGIES LIMITED (GB) 2022-03-10 US disclosed
EP-3818116-A1 OXIDATIVELY CURABLE COATING COMPOSITION Catexel Technologies Limited (GB) 2021-05-12 EP disclosed
EP-3818101-A1 LIQUIDS Borchers Catalyst (UK) Limited (GB) 2021-05-12 EP disclosed
WO-2020008205-A1 OXIDATIVELY CURABLE COATING COMPOSITION CATEXEL TECHNOLOGIES LIMITED (GB) 2020-01-09 WO disclosed
WO-2020008203-A1 LIQUIDS CATEXEL LIMITED (GB) 2020-01-09 WO disclosed
US-5468858-A Sudden death syndrome THE BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY PHYSICAL SCIENCES (US) 1995-11-21 US disclosed
EP-0618881-A4 A PROCESS FOR PREPARING MOLECULAR SIEVES USING 3,7-DIAZABICYCLO[3.3.1]NONANE TEMPLATES. CHEVRON RES & TECH (US) 1995-01-04 EP disclosed
EP-0618881-A1 A PROCESS FOR PREPARING MOLECULAR SIEVES USING 3,7-DIAZABICYCLO[3.3.1]NONANE TEMPLATES CHEVRON RESEARCH AND TECHNOLOGY COMPANY, (US) 1994-10-12 EP disclosed
WO-1994008898-A1 A PROCESS FOR PREPARING MOLECULAR SIEVES USING 3,7-DIAZABICYCLO[3.3.1]NONANE TEMPLATES CHEVRON RESEARCH AND TECHNOLOGY COMPANY, A DIVISIO (US) 1994-04-28 WO disclosed
US-5271921-A Process for preparing molecular sieves using 3,7-diazabicyclo[3.3.1] CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1993-12-21 US disclosed
US-5268481-A Containing a benzene ring BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGE ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) 1993-12-07 US disclosed
US-5043445-A Bis-1,3-diazine heterocyclic derivatives as antiarrhythmic agents OKLAHOMA STATE UNIVERSITY (US) 1991-08-27 US disclosed
US-4980468-A ANTIARRHYTHMIC AGENTS BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) 1990-12-25 US disclosed
US-4910311-A Containing a phenyl or thiophene ring BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL MECHANICAL COLLEGES, ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIV. (US) 1990-03-20 US disclosed
US-4778892-A Certain 3-selena-7-aza-bicyclo[3.3.1]nonanes as antiarrhythmic agents OKLAHOMA STATE UNIVERSITY (US) 1988-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570851-B2 Liquids SOD1, GPX4, SMARCC1 CHRNB4 3686/4885CHRNA3 2740/4885CCR5 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.